Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCHIZOPHRENIA 1 (Disorder) Clear all

Conditions: Schizophrenia
Interventions: RBP-7000; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 42 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Willingboro, New Jersey

Conditions: Healthy
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Tobacco Use Disorder
Interventions: Nicotine patch; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Piscataway, New Jersey

Conditions: Schizophrenia
Interventions: ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • New York, New York

Conditions: Parasite and Infestation Physician-Patient Diagnostic Incongruency
Interventions: No intervention - observational study; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: SCHIZOPHRENIA 1 (Disorder)
Interventions: Paliperidone Palmitate; Drug
Lead sponsor: Alejandro Alva; Network
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Orange, California • Miami, Florida • Chicago, Illinois

Conditions: Schizophrenia
Interventions: SEP-380135, Quinidine Gluconate; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Dimethoxybenzylidene anabaseine (DMXB-A), Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Schizophrenia
Interventions: active H-coil delivered rTMS; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Glendale, California • Philadelphia, Pennsylvania

Conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, Ingestible Event Marker (IEM); Drug · Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Cerritos, California • Garden Grove, California • Long Beach, California + 9 more

Conditions: Clinical High Risk, Early Psychosis, First Episode Psychosis
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 29 Years
Enrollment: 25,000 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia or Schizoaffective Disorder
Interventions: AMG 581, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia, Bipolar I Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more

Conditions: Schizophrenia
Interventions: APN1125, Placebo; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: Brexpiprazole (OPC-34712); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • Culver City, California • Orange, California + 7 more

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
Interventions: Motion Perception Task, Sine Wave Speech Task, Volatility Task, Choice Probabilistic Reversal Task, Kamin Blocking Task, Minnesota Trust Game, Dynamic Trust Game; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 59 Years
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Irvine, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Schizophrenia
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 6 Years
Enrollment: 598 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
Interventions: Motion Perception Task, Sine Wave Speech Task, Volatility Task, Choice Probabilistic Reversal Task, Kamin Blocking Task, Minnesota Trust Game, Dynamic Trust Game; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 59 Years
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2031
U.S. locations: 5
States / cities: Irvine, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Schizophrenia
Interventions: PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq.; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 24
States / cities: Little Rock, Arkansas • Glendale, California • Long Beach, California + 21 more

Conditions: Schizophrenia
Interventions: ASP4345, Matching Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: Lurasidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Culver City, California

Conditions: Tobacco Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Bipolar Disorder, Schizophrenia
Interventions: Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Search by objective public record fields.

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

The Parasite and Infestation Study

Higher-Dose Maintenance With ERZOFRI 351 mg in Adults With Schizophrenia

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Digital Strategies to Advance Help-Seeking Aim 1 and 2

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

Prospective Studies of the Pathogenesis of Schizophrenia

Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Digoxin Drug-Drug Interaction With Lurasidone HCl

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder